Cox analysis of survival
| Variable . | HR (95% CI) . | P . |
|---|---|---|
| Univariable analysis | ||
| Age | 1.02 (0.99-1.04) | .203 |
| Male sex | 1.39 (0.82-2.33) | .219 |
| ln(iFLC) | 1.22 (1.02-1.46) | .024 |
| iFLC > 125 mg/L | 2.00 (1.19-3.37) | .009 |
| NYHA class > 2 | 3.05 (1.83-5.06) | < .001 |
| mLVW thickness | 1.14 (1.06-1.22) | .001 |
| mLVW thickness > 12 mm | 2.84 (1.44-5.59) | .003 |
| EF | 0.96 (0.93-0.98) | .001 |
| EF < 55% | 1.62 (0.97-2.70) | .064 |
| ln(cTnI) | 1.59 (1.26-2.01) | < .001 |
| cTnI > 40 ng/L (url) | 2.85 (1.55-5.24) | .001 |
| cTnI > 70 ng/L | 3.90 (2.16-7.05) | < .001 |
| cTnI > 100 ng/L | 4.64 (2.51-8.58) | < .001 |
| ln(NT-proBNP) | 1.42 (1.20-1.68) | < .001 |
| NT-proBNP > 332 ng/L | 4.06 (1.63-10.14) | .003 |
| NT-proBNP > 2736 ng/L | 2.63 (1.60-4.34) | < .001 |
| ln(hs-cTnT) | 1.78 (1.40-2.27) | < .001 |
| hs-cTnT > 14 ng/L (url) | 2.71 (1.37-5.34) | .004 |
| hs-cTnT > 77 ng/L | 4.33 (2.61-7.18) | < .001 |
| Multivariable analysis of baseline variables | ||
| iFLC > 125 mg/L | 1.72 (1.01-2.91) | .045 |
| NYHA class > 2 | 2.20 (1.23-3.95) | .008 |
| mLVW thickness > 12 mm | 1.36 (0.63-2.92) | .428 |
| EF < 55% | 1.01 (0.59-1.74) | .967 |
| hs-cTnT > 77 ng/L | 3.83 (2.82-6.41) | < .001 |
| Time-dependent multivariable analysis, including baseline variables and hematologic and NT-proBNP response | ||
| iFLC > 125 mg/L | 1.34 (0.75-2.41) | .320 |
| NYHA class > 2 | 1.87 (1.02-3.43) | .043 |
| mLVW thickness > 12 mm | 1.60 (0.72-3.54) | .245 |
| hs-cTnT > 77 ng/L | 4.55 (2.54-8.16) | < .001 |
| NT-proBNP response | 0.45 (0.18-1.10) | .074 |
| NT-proBNP progression | 3.79 (1.84-8.00) | < .001 |
| hs-cTnT increase > 75% | 3.31 (1.81-6.04) | < .001 |
| Hematologic response | 0.69 (0.35-1.37) | .295 |
| Variable . | HR (95% CI) . | P . |
|---|---|---|
| Univariable analysis | ||
| Age | 1.02 (0.99-1.04) | .203 |
| Male sex | 1.39 (0.82-2.33) | .219 |
| ln(iFLC) | 1.22 (1.02-1.46) | .024 |
| iFLC > 125 mg/L | 2.00 (1.19-3.37) | .009 |
| NYHA class > 2 | 3.05 (1.83-5.06) | < .001 |
| mLVW thickness | 1.14 (1.06-1.22) | .001 |
| mLVW thickness > 12 mm | 2.84 (1.44-5.59) | .003 |
| EF | 0.96 (0.93-0.98) | .001 |
| EF < 55% | 1.62 (0.97-2.70) | .064 |
| ln(cTnI) | 1.59 (1.26-2.01) | < .001 |
| cTnI > 40 ng/L (url) | 2.85 (1.55-5.24) | .001 |
| cTnI > 70 ng/L | 3.90 (2.16-7.05) | < .001 |
| cTnI > 100 ng/L | 4.64 (2.51-8.58) | < .001 |
| ln(NT-proBNP) | 1.42 (1.20-1.68) | < .001 |
| NT-proBNP > 332 ng/L | 4.06 (1.63-10.14) | .003 |
| NT-proBNP > 2736 ng/L | 2.63 (1.60-4.34) | < .001 |
| ln(hs-cTnT) | 1.78 (1.40-2.27) | < .001 |
| hs-cTnT > 14 ng/L (url) | 2.71 (1.37-5.34) | .004 |
| hs-cTnT > 77 ng/L | 4.33 (2.61-7.18) | < .001 |
| Multivariable analysis of baseline variables | ||
| iFLC > 125 mg/L | 1.72 (1.01-2.91) | .045 |
| NYHA class > 2 | 2.20 (1.23-3.95) | .008 |
| mLVW thickness > 12 mm | 1.36 (0.63-2.92) | .428 |
| EF < 55% | 1.01 (0.59-1.74) | .967 |
| hs-cTnT > 77 ng/L | 3.83 (2.82-6.41) | < .001 |
| Time-dependent multivariable analysis, including baseline variables and hematologic and NT-proBNP response | ||
| iFLC > 125 mg/L | 1.34 (0.75-2.41) | .320 |
| NYHA class > 2 | 1.87 (1.02-3.43) | .043 |
| mLVW thickness > 12 mm | 1.60 (0.72-3.54) | .245 |
| hs-cTnT > 77 ng/L | 4.55 (2.54-8.16) | < .001 |
| NT-proBNP response | 0.45 (0.18-1.10) | .074 |
| NT-proBNP progression | 3.79 (1.84-8.00) | < .001 |
| hs-cTnT increase > 75% | 3.31 (1.81-6.04) | < .001 |
| Hematologic response | 0.69 (0.35-1.37) | .295 |
HR indicates hazard ratio; CI, confidence interval; NYHA, New York Heart Association; EF, ejection fraction; and url, upper reference limit.